AP NEWS

Peanut Allergy Pipeline Insights, 2019 Report - ResearchAndMarkets.com

January 23, 2019

DUBLIN--(BUSINESS WIRE)--Jan 23, 2019--The “Peanut Allergy - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

“Peanut Allergy - Pipeline Insight, 2019” report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Peanut Allergy development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

Clinical Non-clinical Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Peanut Allergy

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Peanut Allergy

The report assesses the active Peanut Allergy pipeline products by developmental stage, product type, molecule type, and administration route.

Scope of the report

The report provides a snapshot of the pipeline development for the Peanut Allergy The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Peanut Allergy The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Peanut Allergy The report also covers the dormant and discontinued pipeline projects related to the Peanut Allergy

Key Topics Covered:

1. Report Introduction

2. Peanut Allergy Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Products in Clinical Stage

6. Products in Pre-Clinical and Discovery Stage

7. Therapeutic Assessment

8. Inactive Products

Companies Mentioned

Adverum Biotechnologies Inc Aimmune Therapeutics Inc Alfacyte Ltd Allergy Therapeutics Plc AnaptysBio Inc ASIT Biotech SA Astellas Pharma Inc BioLingus AG DBV Technologies SA HAL Allergy BV

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/kltvwz/peanut_allergy?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190123005354/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Allergy Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH GENERAL HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/23/2019 05:56 AM/DISC: 01/23/2019 05:56 AM

http://www.businesswire.com/news/home/20190123005354/en

AP RADIO
Update hourly